Artiva Biotherapeutics, Inc. - Common Stock (ARTV)
4.3200
-0.1100 (-2.48%)
NASDAQ · Last Trade: Dec 30th, 2:39 PM EST
Detailed Quote
Previous Close
4.430
Open
4.480
Bid
4.300
Ask
4.340
Day's Range
4.250 - 4.522
52 Week Range
1.470 - 11.55
Volume
69,196
Market Cap
-
PE Ratio (TTM)
-10.80
EPS (TTM)
-0.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,761,371
Chart
About Artiva Biotherapeutics, Inc. - Common Stock (ARTV)
Artiva Biotherapeutics, Inc. is a biotechnology company focused on developing innovative cellular therapies for the treatment of cancer. The company primarily harnesses the power of natural killer (NK) cells, a type of immune cell, to create targeted therapies designed to improve patient outcomes in oncology. By leveraging advanced research and technology, Artiva aims to engineer these NK cells to enhance their efficacy against tumors and create transformative treatment options. Its approach emphasizes the importance of harnessing the body's immune system to recognize and attack cancer cells, representing a promising avenue in the fight against different types of malignancies. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Myseum, Inc. (Nasdaq: MYSE) a leader in digital privacy and next-generation social media technology, today announced the successful completion of the sale of its approximately 35% minority ownership interest in RPM Interactive, Inc. (“RPM”), following Avalon GloboCare Corp.’s (Nasdaq: ALBT ) agreement to acquire 100% of RPM .
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences:
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
